OVALEAP

This brand name is authorized in Austria, Estonia, Finland, France, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug OVALEAP contains one active pharmaceutical ingredient (API):

1	Follitropin alfa UNII 076WHW89TW - FOLLITROPIN
	In women, the most important effect resulting from parenteral administration of FSH is the development of mature Graafian follicles.
	Read more about Follitropin alfa

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OVALEAP Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03GA05	Follitropin alfa	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03G Gonadotropins and other ovulation stimulants → G03GA Gonadotropins
Discover more medicines within G03GA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1628636, 1628647, 1628658
ES	Centro de información online de medicamentos de la AEMPS	113871001, 113871002, 113871003
FI	Lääkealan turvallisuus- ja kehittämiskeskus	455692, 584262, 594538
FR	Base de données publique des médicaments	67050131, 67945023, 68787170
GB	Medicines & Healthcare Products Regulatory Agency	311771, 311774, 311777
IL	מִשְׂרַד הַבְּרִיאוּת	8024, 8025, 8026
IT	Agenzia del Farmaco	043029014, 043029026, 043029038
LT	Valstybinė vaistų kontrolės tarnyba	1071579, 1071580, 1071581
NL	Z-Index G-Standaard, PRK	129410, 129429, 129658
PL	Rejestru Produktów Leczniczych	100304458, 100304464, 100304470
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65720001, W65721001, W65722001